The EDN1 Knockout Raji Polyclonal Cells represent a human B lymphocyte polyclonal knockout cell population generated through CRISPR/Cas9-mediated disruption of the EDN1 gene in the Raji cell line. This polyclonal population provides a robust loss-of-function model for investigating endothelin-1 biology, enabling researchers to dissect the peptide’s roles in cellular signaling, proliferation, and survival. The knockout abolishes production of endothelin-1, a secreted vasoconstrictor and mitogen, making these cells ideally suited for functional and mechanistic studies. As a polyclonal knockout pool, the product offers flexibility for assays that benefit from an ensemble of edited cells, avoiding potential clonal artifacts while maintaining a broad representation of the Raji background.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma B lymphocyte line that lacks surface immunoglobulin expression. It is extensively employed in cancer biology and immunology due to its malignant B cell characteristics and defined growth properties. Originating from a human Burkitt’s lymphoma, Raji cells retain key features of transformed B cells, including active antigen presentation machinery and high proliferative capacity, while the EBV genome contributes to constitutive activation of survival pathways such as NF-??B. This background is particularly relevant for studying B cell malignancies and the molecular underpinnings of lymphoma progression, offering a well-characterized platform for gene-edited models.
Endothelin-1, encoded by EDN1, is a potent peptide that primarily signals through two G protein-coupled receptors, endothelin receptor type A (ETA) and type B (ETB). Upon ligand binding, ETA/ETB receptors engage Gq, Gi, and G12/13 proteins to activate diverse downstream effectors, including phospholipase C (PLC)-mediated production of inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium release and protein kinase C (PKC) activation. In parallel, receptor stimulation triggers the Ras-Raf-MEK-ERK (MAPK/ERK) cascade and the PI3K/AKT pathway, promoting cell proliferation, survival, and migration. EDN1 expression is transcriptionally regulated by a network of factors including TNF-??, IL-1??, TGF-??, VEGF, and hypoxia-inducible factor HIF-1??, as well as transcription factors AP-1, NF-??B, and GATA family members. Downstream targets encompass cyclin D1, c-Myc, Bcl-2, VEGF, matrix metalloproteinases MMP-2 and MMP-9, and connective tissue growth factor (CTGF). The peptide is also processed by endothelin-converting enzyme-1 (ECE-1) and modulated by interacting partners such as caveolin-1 and ??-arrestin, which fine-tune signaling duration and subcellular localization.
In the Raji Burkitt’s lymphoma context, EDN1 knockout disrupts autocrine and paracrine endothelin signaling, leading to diminished activation of MAPK/ERK and PI3K/AKT cascades. Since these pathways are critical for malignant B cell proliferation, survival, and invasiveness, the loss of endothelin-1 attenuates pro-tumorigenic phenotypes, evidenced by reduced phosphorylation of ERK and AKT, decreased cyclin D1 and c-Myc levels, and impaired MMP-2/9-dependent migration. The model thus recapitulates the consequences of silencing an oncogenic G protein-coupled receptor network in a lymphoma setting. Furthermore, because Raji cells harbor EBV, the interplay between viral latent gene products and EDN1-driven signals??both of which converge on NF-??B and MAPK modules??can be systematically explored. This knockout population serves as a key tool to validate EDN1 as a therapeutic target in B cell malignancies and to understand how endothelin signaling intersects with viral transformation and immune evasion.
Research applications for these polyclonal knockout cells include dissecting EDN1-dependent proliferation using MTS/MTT assays, apoptosis detection via Annexin V staining, and transwell migration/invasion experiments. Western blotting for phosphorylated ERK and AKT, RT-qPCR for EDN1 mRNA, and ELISA for secreted endothelin-1 allow detailed molecular characterization. Additional assays such as calcium flux measurements, phospho-signaling arrays, and RNA-seq transcriptomic profiling are well-suited to this model. The cells support drug target validation against the endothelin axis, evaluation of therapeutic antibodies, and screening of small-molecule inhibitors targeting ETA/ETB receptors or downstream kinases. Overall, the EDN1 Knockout Raji Polyclonal Cells offer a versatile and physiologically relevant system for advancing biomedical research in cancer and vascular biology. For further technical information or support, please contact Ascent Research.
